SPRINT v. ACCORD: Which Target Will Win in Diabetes?
AHA 2015 | ORLANDO, FL — When the SPRINT trial's substantial cardiovascular event and mortality risk reductions were reported Monday, the big question was why did that trial succeed with a systolic blood pressure target under 120 mm Hg when the ACCORD trial failed with intensive treatment to the same target in diabetes. Read More >>>
Keywords: AHA Annual Scientific Sessions
< Back to Listings